These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17632933)

  • 1. FDA panel backs HIV drug.
    AIDS Read; 2007 Jun; 17(6):294. PubMed ID: 17632933
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA notifications. Maraviroc approved as a CCR5 co-receptor antagonist.
    AIDS Alert; 2007 Sep; 22(9):103. PubMed ID: 18411462
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA advisory committee approves Selzentry.
    AIDS Patient Care STDS; 2009 Nov; 23(11):987. PubMed ID: 19938371
    [No Abstract]   [Full Text] [Related]  

  • 4. Something new under the sun. Maraviroc poised for approval.
    Huff B
    GMHC Treat Issues; 2006; 20(8-12):1-4. PubMed ID: 17569160
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA approves maraviroc tablets.
    AIDS Patient Care STDS; 2007 Sep; 21(9):702. PubMed ID: 17919097
    [No Abstract]   [Full Text] [Related]  

  • 6. Maraviroc--new HIV drug. Emerging options need to be used wisely.
    Vázquez E
    Posit Aware; 2007; 18(4):18-9. PubMed ID: 17682275
    [No Abstract]   [Full Text] [Related]  

  • 7. [CCR5 antagonist Maraviroc: effective and well tolerated. "A very promising substance"].
    Zorn F
    MMW Fortschr Med; 2011 May; 153(18):30-1. PubMed ID: 21604590
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA approval: maraviroc.
    Sax PE
    AIDS Clin Care; 2007 Sep; 19(9):75. PubMed ID: 18398993
    [No Abstract]   [Full Text] [Related]  

  • 9. Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug.
    Kast RE
    J Clin Pharm Ther; 2010 Dec; 35(6):657-63. PubMed ID: 21054456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two new drugs for HIV infection.
    Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
    [No Abstract]   [Full Text] [Related]  

  • 11. Maraviroc: integration of a new antiretroviral drug class into clinical practice.
    Vandekerckhove L; Verhofstede C; Vogelaers D
    J Antimicrob Chemother; 2008 Jun; 61(6):1187-90. PubMed ID: 18400807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious doubts on safety and efficacy of CCR5 antagonists : CCR5 antagonists teeter on a knife-edge.
    Horster S; Goebel FD
    Infection; 2006 Apr; 34(2):110-3. PubMed ID: 16703305
    [No Abstract]   [Full Text] [Related]  

  • 14. Maraviroc approved for use in treatment-experienced CCR5-tropic HIV-1.
    AIDS Alert; 2009 Jan; 24(1):10-2. PubMed ID: 19209462
    [No Abstract]   [Full Text] [Related]  

  • 15. When and how to use maraviroc in HIV-infected patients.
    Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
    AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel HIV treatment approved.
    Groeschen HM
    Am J Health Syst Pharm; 2007 Sep; 64(18):1886. PubMed ID: 17823091
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA notifications. FDA postpones CCR5 Antagonist Review Group meeting.
    AIDS Alert; 2006 Jan; 21(1):11-2. PubMed ID: 16470945
    [No Abstract]   [Full Text] [Related]  

  • 18. Changes in HIV-1 tropism: clinical and prognostic consequences.
    Mosier DE
    Eur J Med Res; 2007 Oct; 12(9):371-4. PubMed ID: 17933716
    [No Abstract]   [Full Text] [Related]  

  • 19. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
    Meanwell NA; Kadow JF
    Curr Opin Investig Drugs; 2007 Aug; 8(8):669-81. PubMed ID: 17668369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.
    van Lelyveld SF; Wensing AM; Hoepelman AI
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1241-7. PubMed ID: 23113664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.